A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma.

Yun Bin Lee Joon Yeul Nam Eun-Ju Cho Jeong-Hoon Lee Su Jong Yu Hyo Cheol Kim Jin Chul Paeng Jung Hwan Yoon Yun Joon Kim

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

In patients with locally advanced unresectable HCC, the combination of Y90-radioembolization and durvalumab demonstrated promising efficacy and safety, warranting further evaluation in large-scale controlled trials.

Keyphrases

locally advanced
liver metastases
rectal cancer
neoadjuvant chemotherapy
squamous cell carcinoma
radiation therapy
phase ii study
clinical trial
study protocol
phase ii
randomized controlled trial
lymph node
double blind